You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 33 No. 7, July 1976 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Comparative doses and costs of antipsychotic medication

J. M. Davis

It is clinically useful to have a table listing the equivalent doses of the various neuroleptics to a standard, such as chlorpromazine. This article derives such data by reviewing double-blind controlled studies that used a flexible dosage schedule of neuroleptics in treating schizophrenic patients. Each neuroleptic is then converted to 100-mg chlorpromazine equivalents. This empirically derived dosage comparability table is compared with a similar table derived from the opinions of experts. Since these comparable doses produce equivalent amounts of antipsychotic activity, the cost to provide such medication was then calculated, and a table comparing the costs of the different neuroleptics was constructed. In absolute amounts, the cost differences between drugs are small. However, for any drug, large savings accrue when the largest possible capsule or tablet to achieve the desired dose is prescribed.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Abnormal Superior Temporal Connectivity During Fear Perception in Schizophrenia
Leitman et al.
Schizophr Bull 2008;34:673-678.
ABSTRACT | FULL TEXT  

Limbic Activation Associated With Misidentification of Fearful Faces and Flat Affect in Schizophrenia
Gur et al.
Arch Gen Psychiatry 2007;64:1356-1366.
ABSTRACT | FULL TEXT  

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis et al.
Arch Gen Psychiatry 2003;60:553-564.
ABSTRACT | FULL TEXT  

Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations
Hoffman et al.
Arch Gen Psychiatry 2003;60:49-56.
ABSTRACT | FULL TEXT  

Neurological Signs and the Heterogeneity of Schizophrenia
Arango et al.
Am. J. Psychiatry 2000;157:560-565.
ABSTRACT | FULL TEXT  

Longitudinal Study of Cognitive Function in First-Episode and Recent-Onset Schizophrenia
Gold et al.
Am. J. Psychiatry 1999;156:1342-1348.
ABSTRACT | FULL TEXT  

Selective Speech Perception Alterations in Schizophrenic Patients Reporting Hallucinated "Voices"
Hoffman et al.
Am. J. Psychiatry 1999;156:393-399.
ABSTRACT | FULL TEXT  

L-dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia
Owens et al.
J Psychopharmacol 1994;8:204-212.
ABSTRACT  

Psychotropic Drug Prescribing to Chronic Schizophrenics in a Hong Kong Hospital
Chiu et al.
International Journal of Social Psychiatry 1991;37:187-191.
ABSTRACT  

Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs
Rebec et al.
Science 1985;227:438-440.
ABSTRACT  

Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment
Waddington et al.
Science 1983;220:530-532.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1976 American Medical Association. All Rights Reserved.